U.S. flag

An official website of the United States government

Display Settings:

Format
Sort by

Send to:

Choose Destination

Links from Books

Items: 3

1.
Futibatinib, an Irreversible FGFR1–4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF/FGFR Aberrations: A Phase I Dose-Expansion Study
Funda Meric-Bernstam, Rastislav Bahleda, Cinta Hierro, Marc Sanson, John Bridgewater, Hendrik-Tobias Arkenau, Ben Tran, Robin Kate Kelley, Joon Oh Park, Milind Javle, Yaohua He, Karim A. Benhadji, Lipika Goyal
Cancer Discov. 2022 Feb 1; 12(2): 402–415. Published online 2021 Sep 22. doi: 10.1158/2159-8290.CD-21-0697
PMCID:
PMC9762334
AbstractArticlePDF–9.7M
2.
Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1–4 inhibitor in patients with advanced solid tumors
R. Bahleda, F. Meric-Bernstam, L. Goyal, B. Tran, Y. He, I. Yamamiya, K. A. Benhadji, I. Matos, H.-T. Arkenau
Ann Oncol. Author manuscript; available in PMC 2022 Dec 12.
Published in final edited form as: Ann Oncol. 2020 Oct; 31(10): 1405–1412. Published online 2020 Jul 2. doi: 10.1016/j.annonc.2020.06.018
PMCID:
PMC9743148
AbstractArticlePDF–677K
3.
Fibroblast growth factor receptors in cancer: genetic alterations, diagnostics, therapeutic targets and mechanisms of resistance
Melanie A. Krook, Julie W. Reeser, Gabrielle Ernst, Hannah Barker, Max Wilberding, Gary Li, Hui-Zi Chen, Sameek Roychowdhury
Br J Cancer. 2021 Mar 2; 124(5): 880–892. Published online 2020 Dec 3. doi: 10.1038/s41416-020-01157-0
PMCID:
PMC7921129
AbstractArticlePDF–1.2M

Display Settings:

Format
Sort by

Send to:

Choose Destination

Supplemental Content

Filter your results:

Find related data

Recent activity

Clear Turn Off Turn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
You are here: NCBI > Literature > PubMed Central (PMC)
Support Center